Medications for Opioid Use Disorder Differentially Modulate Intrinsically Photosensitive Retinal Ganglion Cell Function, Sleep, and Circadian Rhythms: Implications for Treatment (MOUD)

Status: Recruiting
Location: See all (2) locations...
Intervention Type: Device, Other, Behavioral
Study Type: Observational
SUMMARY

Opioid use disorder (OUD) is a treatable medical illness with three medications FDA approved for treatment. However, persons with OUD report significant sleep disturbance, even when treated with medications for opioid use disorder, leading to high rates of relapse. In this project, we will investigate a special set of photosensitive neurons in the retina as an underlying mechanism for circadian rhythm and sleep disturbance from opioid use and medications for OUD that could lead to novel intervention and improve treatment outcomes.

Eligibility
Participation Requirements
Sex: All
Minimum Age: 18
Maximum Age: 80
Healthy Volunteers: t
View:

• Adults (18+)

• prescribed one of three medications for opioid use disorder (methadone, XR-NTX, buprenorphine) or healthy control

• stable on MOUD (no dose change) for the past month

• positive on urine drug screen (UDS) for buprenorphine or methadone if prescribed those medications

Locations
United States
Alabama
University of Alabama at Birmingham
NOT_YET_RECRUITING
Birmingham
University of Alabama at Birmingham
RECRUITING
Birmingham
Contact Information
Primary
Karen Cropsey, PsyD
kcropsey@uabmc.edu
205-975-7809
Backup
Brionna Smith, B.S.
cropseylab@uabmc.edu
205-975-7809
Time Frame
Start Date: 2025-01-06
Estimated Completion Date: 2029-01-01
Participants
Target number of participants: 200
Treatments
MOUD therapy methadone
50 methadone participants
MOUD therapy buprenorphine
50 buprenorphine participants
MOUD therapy extended-release naltrexone
50 extended-release naltrexone (XR-NTX) participants
Non-opioid using controls
non-opioid using controls
Related Therapeutic Areas
Sponsors
Collaborators: National Institute on Drug Abuse (NIDA)
Leads: University of Alabama at Birmingham

This content was sourced from clinicaltrials.gov